call 1800 257 600 email [email protected]

Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer

ACTRN 12620001198910

Brief Summary

The purpose of this study is to determine if larger doses of radiation given over a shorter period of time, as compared to standard radiation therapy, given with chemotherapy and followed by immunotherapy is safe for participants.

Intervention/Treatment

  • Drug: Paclitaxel.
  • Drug: Carboplatin.
  • Drug: Durvalumab

Inclusion Criteria

  1. Unresectable locally advanced Non-small cell lung carcinoma.
  2. Considered suitable to receive chemoradiation and immunotherapy.
  3. ECOG performance status 0-2.

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.